Literature DB >> 16703558

Endogenous endophthalmitis by Propionibacterium acnes associated with leflunomide and adalimumab therapy.

J A Montero1, J M Ruiz-Moreno, A E Rodríguez, C Ferrer, E Sanchis, J L Alio.   

Abstract

PURPOSE: To report a case of unusual endogenous endophthalmitis associated with the use of leflunomide and adalimumab.
METHODS: A 48-year-old woman on treatment with leflunomide and adalimumab for rheumatoid arthritis developed an endogenous endophthalmitis caused by Propionibacterium acnes. Diagnosis was confirmed by polymerase chain reaction and positive cultures. The patient underwent surgical treatment and intravitreal vancomycin, but the eye developed retinal fibrosis and untreatable retinal detachment.
RESULTS: This report of endogenous endophthalmitis associated with the use of anti-tumor necrosis factor alpha (anti -TNF-a) drugs is consistent with those in the literature. P. acnes may induce pathologic reactions in compromised patients and cause endophthalmitis, but only after ocular surgery or in intravenous drug users. The Naranjo probability scale indicated a probable relationship between the drugs and the infection.
CONCLUSIONS: Awareness of atypical infectious conditions in patients on anti-TNF-a drugs is critical for early diagnosis and good outcome.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16703558     DOI: 10.1177/112067210601600225

Source DB:  PubMed          Journal:  Eur J Ophthalmol        ISSN: 1120-6721            Impact factor:   2.597


  7 in total

Review 1.  [Infectious complications of biologic therapy in patients with rheumatoid arthritis].

Authors:  D Meyer-Olson; K Hoeper; R E Schmidt
Journal:  Z Rheumatol       Date:  2010-12       Impact factor: 1.372

2.  Suppressed wound healing in a patient with rheumatoid arthritis taking leflunomide (arava).

Authors:  D Miller Wise
Journal:  Perm J       Date:  2011

Review 3.  Propionibacterium acnes: from commensal to opportunistic biofilm-associated implant pathogen.

Authors:  Yvonne Achermann; Ellie J C Goldstein; Tom Coenye; Mark E Shirtliff
Journal:  Clin Microbiol Rev       Date:  2014-07       Impact factor: 26.132

4.  Adalimumab in the therapy of uveitis in childhood.

Authors:  Sabine Biester; Christoph Deuter; Hartmut Michels; Renate Haefner; Jasmin Kuemmerle-Deschner; Deshka Doycheva; Manfred Zierhut
Journal:  Br J Ophthalmol       Date:  2006-10-11       Impact factor: 4.638

Review 5.  Identifying and Treating Ocular Manifestations in Psoriasis.

Authors:  Mahsaw Motlagh; Christopher Fortenbach; Howard I Maibach; Bobeck S Modjtahedi
Journal:  Am J Clin Dermatol       Date:  2021-11-03       Impact factor: 7.403

Review 6.  Ocular adverse effects of therapeutic biologics.

Authors:  Helio V Neves da Silva; John Placide; Anne Duong; Yasmyne Ronquillo; Shannon McCabe; Majid Moshirfar
Journal:  Ther Adv Ophthalmol       Date:  2022-04-26

Review 7.  A review of ocular adverse events of biological anti-TNF drugs.

Authors:  Fernanda Nicolela Susanna; Carlos Pavesio
Journal:  J Ophthalmic Inflamm Infect       Date:  2020-04-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.